Patents Assigned to The Institute for Human Genetics and Biochemistry
-
Patent number: 10539551Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with Human Immunodeficiency Virus-1 (HIV-1) infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, cell surface Human Leucocyte Elastase (HLEcs) and Lipoprotein Receptor-related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.Type: GrantFiled: April 3, 2017Date of Patent: January 21, 2020Assignees: The Institute for Human Genetics and BiochemistryInventor: Cynthia L. Bristow
-
Patent number: 9612233Abstract: A previously unrecognized fundamental property of ?1Proteinase Inhibitor (?1PI) is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, Human Leukocyte Elastase Cell Surface (HLECS) and Low Density Lipoprotein-Receptor Related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.Type: GrantFiled: November 22, 2011Date of Patent: April 4, 2017Assignees: The Institute for Human Genetics and BiochemistryInventor: Cynthia L. Bristow
-
Publication number: 20130017601Abstract: A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein.Type: ApplicationFiled: February 3, 2012Publication date: January 17, 2013Applicant: INSTITUTE FOR HUMAN GENETICS AND BIOCHEMISTRYInventor: Cynthia L. Bristow
-
Publication number: 20120172286Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HW-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, HLECS and LRP, influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.Type: ApplicationFiled: November 22, 2011Publication date: July 5, 2012Applicant: Institute for Human Genetics and BiochemistryInventor: Cynthia L. Bristow
-
Publication number: 20080009442Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, HLECS and LRP, influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.Type: ApplicationFiled: December 5, 2006Publication date: January 10, 2008Applicant: Institute for Human Genetics and BiochemistryInventor: Cynthia Bristow
-
Patent number: 7189826Abstract: Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.Type: GrantFiled: September 20, 2002Date of Patent: March 13, 2007Assignee: Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 7122638Abstract: Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.Type: GrantFiled: September 20, 2002Date of Patent: October 17, 2006Assignee: The Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 6610833Abstract: Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.Type: GrantFiled: December 28, 1999Date of Patent: August 26, 2003Assignee: The Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Publication number: 20030144486Abstract: Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.Type: ApplicationFiled: September 20, 2002Publication date: July 31, 2003Applicant: The Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 6391635Abstract: Disclosed herein are method for producing hydridoma cell lines producing monoclonal human natural IgM antibodies and hybridoma cells produced by the methods. The antibodies are the monoclonal equivalents of circulating human natural antibodies.Type: GrantFiled: May 23, 2000Date of Patent: May 21, 2002Assignee: Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 5872012Abstract: The present invention is directed to protamine-reactive, IgM antibodies, and their uses in prognosis, diagnosis, and therapy. In a specific embodiment, the invention relates to low affinity binding, protamine-reactive serum IgM antibodies. In particular, such antibodies can recognize a sequence comprising four arginyl residues, including a triplet, within a six amino acid residue sequence. Such antibodies may be natural antibodies (i.e., not induced). A low affinity subset of serum protamine-reactive IgM antibodies may be assayed for prognosis or diagnosis of AIDS. Such antibodies are detectable in sera of normal subjects and HIV-infected individuals who subsequently exhibit a significant period of latency, but are absent or deficient in sera of individuals diagnosed with AIDS and sera of HIV infected individuals, who though asymptomatic at the time of the sampling, proceed to AIDS within a relatively short time.Type: GrantFiled: July 5, 1994Date of Patent: February 16, 1999Assignee: The Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 5606026Abstract: An isolated human natural IgM antibody immunoreactive with an epitope present on HIV-1 Tat protein is provided. Additionally, a method for the prognosis or diagnosis of AIDS in an individual infected with HIV including the steps of:obtaining a body fluid from the individual,detecting or measuring natural human IgM antibodies in the body fluid of the individual and determining a .DELTA.20-.DELTA.2 value, andcomparing the .DELTA.20-.DELTA.2 value obtained from the individual with a .DELTA.20-.DELTA.2 value obtained from clinically normal, non-HIV infected humans,wherein the individual has AIDS or will progress to AIDS within about two years if the individual's .DELTA.20-.DELTA.2 value is significantly decreased relative to the .DELTA.20-.DELTA.2 value obtained from the clinically normal humans, is provided.Type: GrantFiled: April 26, 1993Date of Patent: February 25, 1997Assignee: The Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman